Cognition, schizophrenia, and the atypical antipsychotic drugs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 96, Issue 24, 1999, Pages 13591-13593

  Meltzer, H Y ^a   Park, S ^a   Kessler, R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BRAIN BLOOD FLOW; COGNITIVE DEFECT; DOPAMINERGIC ACTIVITY; DRUG CHOICE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR CORTEX; NOTE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION; COGNITIVE THERAPY; HUMANS; MEMORY; SCHIZOPHRENIA;

EID: 0033598803     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.96.24.13591     Document Type: Note

References (45)